Sarepta Therapeutics (SRPT) Gains on Bullish Article

Sarepta Therapeutics (NASDAQ: SRPT) is gaining pre-open after TheStreet's Adam Feuerstein saying the drug could be approved despite the negative panel.

Feuerstein commented, "Minutes after the advisory panel adjourned on Monday night, Woodcock met with some of the DMD boys and their families. Terri Ellsworth posted a picture of a smiling Woodcock standing next to her son, Billy, on her Facebook page."

LINK

Shares of SRPT are up 14% pre-open.

You May Also Be Interested In

• Super Micro Computer (SMCI) Falls 6%
• Duolingo (DUOL) to Join S&P MidCap 400; Cable One (CABO) to Join S&P SmallCap 600
• Zuora (ZUO) spikes into halt on takeover rumors